细胞治疗后SARS-CoV-2疫苗接种的抗原特异性T细胞反应
本研究为前瞻性多中心队列的子研究,评估68例接受allo-HCT、auto-HCT或CAR-T治疗患者接种SARS-CoV-2 mRNA疫苗后的功能性T细胞反应。结果显示疫苗接种诱导了显著的抗原特异性CD4+和CD8+T细胞反应,且早期接种(<4个月)未损害功能性T细胞反应。
要点
- mRNA疫苗接种后在所有细胞治疗组均诱导功能性Th1偏向T细胞反应。
- 早期接种(<4个月)与后期接种的功能性T细胞反应无差异。
- 功能性T细胞反应与基线CD19+B细胞计数和抗体反应相关。
核心结论
- mRNA SARS-CoV-2疫苗接种在allo-HCT、auto-HCT和CAR-T治疗后均能引发功能性Th1偏向T细胞反应。
- 细胞治疗后早期(<4个月)启动SARS-CoV-2疫苗接种未损害功能性T细胞反应。
研究设计与样本
- 前瞻性多中心队列的子研究,纳入68例患者(allo-HCT 28例,auto-HCT 22例,CAR-T 18例)。
- 采用光谱流式细胞术评估抗原特异性CD4+和CD8+T细胞反应。
主要发现
- 疫苗接种后所有细胞治疗组的抗原特异性CD4+和CD8+T细胞干扰素γ和肿瘤坏死因子α产生显著增加。
- 反应主要由CD4+中央记忆T细胞和细胞毒性CD8+T细胞亚群驱动。
- 功能性T细胞反应与基线CD19+B细胞计数(P = .002)和接种后抗体反应(P< .01)相关,但与SARS-CoV-2特异性TCR广度或深度无关。
- 即使B细胞计数低或抗体反应缺失的患者也可检测到功能性T细胞反应。
临床怎么用
- 细胞治疗后早期(<4个月)即可启动SARS-CoV-2疫苗接种,无需担心损害功能性T细胞反应。
- 功能性T细胞反应可在B细胞计数低或抗体反应缺失的患者中检测到,提示细胞免疫可独立于体液免疫。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The optimal timing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination after cellular therapies remains uncertain. In a previous prospective multicenter cohort (n = 466), we found no differences in humoral or SARS-CoV-2-specific T-cell receptor (TCR) responses between patients vaccinated early (<4 months) vs later (4-12 months) after allogeneic hematopoietic cell transplant (allo-HCT), autologous HCT (auto-HCT), or chimeric antigen receptor T-cell (CAR-T) therapy. In this substudy, we evaluated functional T-cell responses in 68 patients (allo-HCT, n = 28; auto-HCT, n = 22; CAR-T, n = 18) that were clinically and immunophenotypically similar to that of the overall cohort. Antigen-specific CD4+ and CD8+ T-cell responses to SARS-CoV-2 messenger RNA (mRNA) vaccination were assessed by spectral flow cytometry. Functional responses were correlated with baseline immune reconstitution parameters, antibody responses, and SARS-CoV-2-specific TCR repertoire metrics. Vaccination induced significant increases in antigen-specific interferon gamma and tumor necrosis factor α production by both CD4+ and CD8+ T cells across all cellular therapy groups. Responses were primarily driven by CD4+ central memory and cytotoxic CD8+ T-cell subsets. Functional T-cell responses correlated with baseline CD19+ B-cell counts (P = .002) and postvaccination antibody responses (P< .01) but not with SARS-CoV-2-specific TCR breadth or depth. Notably, functional T-cell responses were detectable even in patients with low B-cell counts or absent antibody responses. We conclude that mRNA SARS-CoV-2 vaccination elicits functional, T helper 1-skewed T-cell responses after allo-HCT, auto-HCT, and CAR-T therapy. Initiation of SARS-CoV-2 vaccination early after cellular therapy (<4 months) was not associated with impaired functional T-cell responses.
引用
- Einarsdottir S, Fei T, Singh K, et al. Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy. Blood Adv. 2026. PMID: 41941698. doi:10.1182/bloodadvances.2026019614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。